SG11202105685TA - Methods and materials for increasing transcription factor eb polypeptide levels - Google Patents
Methods and materials for increasing transcription factor eb polypeptide levelsInfo
- Publication number
- SG11202105685TA SG11202105685TA SG11202105685TA SG11202105685TA SG11202105685TA SG 11202105685T A SG11202105685T A SG 11202105685TA SG 11202105685T A SG11202105685T A SG 11202105685TA SG 11202105685T A SG11202105685T A SG 11202105685TA SG 11202105685T A SG11202105685T A SG 11202105685TA
- Authority
- SG
- Singapore
- Prior art keywords
- materials
- methods
- transcription factor
- polypeptide levels
- increasing transcription
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962788049P | 2019-01-03 | 2019-01-03 | |
US201962879374P | 2019-07-26 | 2019-07-26 | |
PCT/US2020/012268 WO2020142748A1 (en) | 2019-01-03 | 2020-01-03 | Methods and materials for increasing transcription factor eb polypeptide levels |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105685TA true SG11202105685TA (en) | 2021-06-29 |
Family
ID=71406977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105685TA SG11202105685TA (en) | 2019-01-03 | 2020-01-03 | Methods and materials for increasing transcription factor eb polypeptide levels |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220112218A1 (en) |
EP (1) | EP3906033A4 (en) |
JP (1) | JP2022516631A (en) |
KR (1) | KR20210111787A (en) |
CN (1) | CN113316453A (en) |
AU (1) | AU2020204717A1 (en) |
BR (1) | BR112021012950A2 (en) |
CA (1) | CA3123902A1 (en) |
IL (1) | IL284403A (en) |
MX (1) | MX2021008152A (en) |
SG (1) | SG11202105685TA (en) |
WO (1) | WO2020142748A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
CZ309449B6 (en) * | 2020-12-24 | 2023-01-25 | Ústav experimentální botaniky AV ČR, v. v. i. | Quinazoline derivatives as selective cyclooxygenase-1 inhibitors |
CN113248518B (en) * | 2021-06-21 | 2022-03-25 | 山东大学 | Pyrimidine piperazine derivative and preparation method and application thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
EP1317449B1 (en) * | 2000-09-15 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
JP2005503425A (en) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | Delivery of drug ester by the prescribed inhalation route |
US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
US7262200B2 (en) * | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
CL2004000409A1 (en) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | COMPOUNDS DERIVED FROM 2- (REPLACED CILO) -1- (AMINO OR REPLACED OXI) -CHINAZOLINE, INHIBITORS OF IONIC SODIUM AND CALCIUM VOLTAGE DEPENDENTS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF ACUTE PAIN, CHRONIC, NEU |
US7198926B2 (en) * | 2003-05-08 | 2007-04-03 | E. I. Du Pont De Nemours And Company | Preparation of (E)- and (Z)-2-methyl-2-butenoic acids |
WO2008157500A1 (en) * | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
CA2731926A1 (en) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
EP2324022A1 (en) * | 2008-08-05 | 2011-05-25 | Boehringer Ingelheim International GmbH | Substituted naphthyridines and use thereof as medicines |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
CN107205976A (en) * | 2014-11-19 | 2017-09-26 | 拉什大学医学中心 | Composition and method for treating lysosome illness |
WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
EP3538091A4 (en) * | 2016-11-08 | 2020-06-10 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF |
WO2018089493A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PYRROLE mTORC INHIBITORS AND USES THEREOF |
US11339144B2 (en) * | 2017-04-10 | 2022-05-24 | Navitor Pharmaceuticals, Inc. | Heteroaryl Rheb inhibitors and uses thereof |
-
2020
- 2020-01-03 US US17/420,597 patent/US20220112218A1/en active Pending
- 2020-01-03 EP EP20736104.9A patent/EP3906033A4/en active Pending
- 2020-01-03 AU AU2020204717A patent/AU2020204717A1/en active Pending
- 2020-01-03 BR BR112021012950-2A patent/BR112021012950A2/en unknown
- 2020-01-03 WO PCT/US2020/012268 patent/WO2020142748A1/en unknown
- 2020-01-03 MX MX2021008152A patent/MX2021008152A/en unknown
- 2020-01-03 CN CN202080007921.4A patent/CN113316453A/en active Pending
- 2020-01-03 KR KR1020217022772A patent/KR20210111787A/en unknown
- 2020-01-03 SG SG11202105685TA patent/SG11202105685TA/en unknown
- 2020-01-03 CA CA3123902A patent/CA3123902A1/en active Pending
- 2020-01-03 JP JP2021538743A patent/JP2022516631A/en active Pending
-
2021
- 2021-06-27 IL IL284403A patent/IL284403A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022516631A (en) | 2022-03-01 |
EP3906033A1 (en) | 2021-11-10 |
US20220112218A1 (en) | 2022-04-14 |
CN113316453A (en) | 2021-08-27 |
IL284403A (en) | 2021-08-31 |
AU2020204717A1 (en) | 2021-06-10 |
BR112021012950A2 (en) | 2021-09-14 |
CA3123902A1 (en) | 2020-07-09 |
MX2021008152A (en) | 2021-10-13 |
WO2020142748A1 (en) | 2020-07-09 |
EP3906033A4 (en) | 2022-11-09 |
KR20210111787A (en) | 2021-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284403A (en) | Methods and materials for increasing transcription factor eb polypeptide levels | |
GB2587328B (en) | Composite materials and methods | |
SG11202111468SA (en) | Materials and methods for protein production | |
EP4021928A4 (en) | Modified n-810 and methods therefor | |
EP3839034C0 (en) | Culture material and application for same | |
EP4041241A4 (en) | Methods for treating myelofibrosis and related conditions | |
GB201903827D0 (en) | New compounds and methods | |
IL285546A (en) | Compounds and methods for reducing kcnt1 expression | |
EP4009777A4 (en) | Transcription factor nterf221 and methods of using the same | |
PL3938074T3 (en) | Mineralization cartridge and method for the operation thereof | |
GB2587469B (en) | Inceptor and method | |
EP3768387A4 (en) | Immunosuppressive materials and related methods | |
IL290109A (en) | Cells for improved immunotherapy and uses thereof | |
GB201911127D0 (en) | Materials and methods | |
EP4082767A4 (en) | Reinforcing material and reinforcing structure | |
GB201911134D0 (en) | Materials and method | |
EP3965796A4 (en) | Methods and materials for treating cardiovascular diseases | |
EP3819047C0 (en) | Optimised steel material | |
EP4023663A4 (en) | Polypeptide and application thereof | |
GB201906902D0 (en) | Composition and method | |
IL289955A (en) | Materials and methods for multidirectional biotransportation | |
GB201911629D0 (en) | Materials and methods | |
GB201911133D0 (en) | Materials and methods | |
GB201911136D0 (en) | Materials and methods | |
GB201911130D0 (en) | MAterials and methods |